Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with down syndrome and acute lymphoblastic leukemia

Haematologica

Volumn 95, Issue 7, 2010, Pages 1106-1113

  Buitenkamp, Trudy D ^a   Mathôt, Ron A A ^b   de Haas, Valerie ^c   Pieters, Rob ^a,c   Michel Zwaan, C ^a,c  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

Author keywords

Acute lymphoblastic leukemia; Down syndrome; Methotrexate; Metrotrexate pharmacokinetics

Indexed keywords

CYTARABINE; DI ADRESON FAQUOSUM; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BRAIN DISEASE; CHILD; CONTROLLED STUDY; DOWN SYNDROME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HEMIPARESIS; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PATIENT MONITORING; POPULATION BASED CASE CONTROL STUDY; RETROSPECTIVE STUDY; SEIZURE; UNCONSCIOUSNESS; ADOLESCENT; CASE CONTROL STUDY; COMPLICATION; DOSE RESPONSE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN SYNDROME; FEMALE; HUMANS; MALE; METHOTREXATE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES;

EID: 77954519312     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.019778     Document Type: Article

References (41)

1. Weijerman ME, van Furth AM, Vonk Noordegraaf A, van Wouwe JP, Broers CJ, Gemke RJ. Prevalence, neonatal characteristics, and first-year mortality of Down syndrome: a national study. J Pediatr. 2008;152(1):15-9.
2. Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M, et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2005;106(13): 4043-9.
3. Chessells JM, Harrison G, Rchards SM, Bailey CC, Hill FG, Gibson BE, Harm IM. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child. 2001;85(4):321-5.
4. Dordelmann M, Schrappe M, Reiter A, Zimmermann M, Graf N, Schott G, et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia. 1998;12(5):645-51.
5. Zeller B, Gustafsson G, Forestier E,Abrahamsson J, Clausen N, Heldrup J, et al; Nordic Society of Paediatric Haematology and and Oncology (NOPHO). Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol. 2005;128(6):797-804.
6. Forestier E, Izraeli S, Beverloo B, Haas O,Pession A, Michalova K, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008;111(3):1575-83.
7. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000;355(9199):165-9.
8. Moericke A ZM, Schwarz C, Mann G, Schmid H, Niemeyer C, Schrappe M. Excellent event-free survival despite higher incidence of treatment-related toxicity and mortility in Down syndrome patients with acute lymphoblastic leukemia as compared to patients without Down syndrome: data from the ALL-BFM 2000 trial P018. 5th Biannual Symposium on Childhood Leukemia 2006 Noordwijkerhout; 2006. p. 45-6.
9. Stanulla M, Cario G, Meissner B, Schrauder A, Moricke A, Riehm H, Schrappe M. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia-a perspective from the BFM Study Group. Blood Cells Mol Dis. 2007; 39(2):160-3.
10. Kager L, Cheok M, Yang W, Zaza G, Cheng Q, Panetta JC, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest. 2005;115(1):110-7.
11. Rots MG, Pieters R, Kaspers GJ, Veerman AJ, Peters GJ, Jansen G. Classification of ex vivo methotrexate resistance in acute lymphoblastic and myeloid leukaemia. Br J Haematol. 2000;110(4):791-800.
12. Rots MG, Pieters R, Peters GJ, Noordhuis P,van Zantwijk CH, Kaspers GJ, et al. Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood. 1999;93(5):1677-83.
13. Masson E, Relling MV, Synold TW, Liu Q,Schuetz JD, Sandlund JT, et al. Accumulation of methotrexate polygluta-mates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest. 1996;97(1):73-80.
14. Peeters MA, Rethore MO, Lejeune J. In vivo folic acid supplementation partially corrects in vitro methotrexate toxicity in patients with Down syndrome. Br J Haematol. 1995;89(3):678-80.
15. Taub JW, Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer. 2005;44(1):33-9.
16. Garre ML, Relling MV, Kalwinsky D,Dodge R, Crom WR, Abromowitch M, et al. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr. 1987;111(4):606-12.
17. Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, van Wering ER, et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia. 2002;16(6):1099-111.
18. Veerman AJ, Kamps WA, van den Berg H,van den Berg E, Bokkerink JP, Bruin MC, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol. 2009;10(10): 957-66.
19. Beal SL, Boeckman AJ, Sheiner L. NON-MEM: Users Guides. University of California at San Francisco; 1988-1992.
20. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303-32.
21. Ette EI. Statistical graphics in pharmacokinetics and pharmacodynamics: a tutorial. Ann Pharmacother. 1998;32(7-8):818-28.
22. Ette EI, Sun H, Ludden TM. Balanced designs in longitudinal population pharmacokinetic studies. J Clin Pharmacol. 1998;38(5):417-23.
23. Ette EI, Sun H, Ludden TM. Ignorability and parameter estimation in longitudinal pharmacokinetic studies. J Clin Pharmacol. 1998;38(3):221-6.
24. Peeters M, Poon A. Down syndrome and leukemia: unusual clinical aspects and unexpected methotrexate sensitivity. Eur J Pediatr. 1987;146(4):416-22.
25. Shah N, Al-Ahmari A, Al-Yamani A, Dupuis L, Stephens D, Fiitzler J. Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome. Pediatr Blood Cancer 2009;52(1):14-9.
26. Aumente D, Buelga DS, Lukas JC, Gomez P, Torres A, Garcia MJ. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet. 2006; 45(12):1227-38.
27. Plard C, Bressolle F, Fakhoury M, Zhang D,Yacouben K, Rieutord A, Jacqz-Aigrain E. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2007;60(4):609-20.
28. Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, Evans WE. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol. 1994;12(8):1667-2.
29. Wall AM, Gajjar A, Link A, Mahmoud H, Pui CH, Relling MV. Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia. 2000;14(2):221-5.
30. Ueland PM, Refsum H, Christensen B. Methotrexate sensitivity in Down's syndrome: a hypothesis. Cancer Chemother Pharmacol. 1990;25(5):384-6.
31. Zwaan MC, Reinhardt D, Fiitzler J, Vyas P. Acute leukemias in children with Down syndrome. Pediatr Clin North Am. 2008; 55(1):53-70.
32. Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Janka-Schaub GE, van Zantwijk CH, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood. 2002;99(1):245-51.
33. von Stackelberg A, Hartmann R, Buhrer C, Fengler R, Janka-Schaub G, Reiter A, et al; Group A-RBS. High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia. Blood. 2008;111 (5):2573-80.
34. Belkov VM, Krynetski EY, Schuetz JD, Yanishevski Y, Masson E, Mathew S, et al. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood. 1999; 93(5):1643-50.
35. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer. 2006;6(2):117-29.
36. de Jonge R, Tissing WJ, Hooijberg JH, Jansen G, Kaspers GJ, Lindemans J, et al. Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood. 2009;113(10):2284-9.
37. Huang L, Tissing WJ, de Jonge R, van Zelst BD, Pieters R. Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia. 2008;22(9):1798-800.
38. Kishi S, Cheng C, French D, Pei D, Das S, Cook EH, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007;109(10):4151-7.
39. Frost BM, Gustafsson G, Larsson R, Nygren P, Lonnerholm G. Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?. Leukemia. 2000;14(5):943-4.
40. Yamada S, Hongo T, Okada S, Watanabe C, Fujii Y, Hori H, et al. Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome. Int J Hematol. 2001;74(4):428-36.
41. Taub JW, Stout ML, Buck SA, Huang X, Vega RA, Becton DL, Ravindranath Y. Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubidn. Leukemia. 1997;11(9):1594-5.